NL930133I2 - Vaccin tegen hepatitis B virus, werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin. - Google Patents

Vaccin tegen hepatitis B virus, werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin.

Info

Publication number
NL930133I2
NL930133I2 NL930133C NL930133C NL930133I2 NL 930133 I2 NL930133 I2 NL 930133I2 NL 930133 C NL930133 C NL 930133C NL 930133 C NL930133 C NL 930133C NL 930133 I2 NL930133 I2 NL 930133I2
Authority
NL
Netherlands
Prior art keywords
vaccine
virus
preparation
eukaryotic cells
against hepatitis
Prior art date
Application number
NL930133C
Other languages
English (en)
Other versions
NL930133I1 (nl
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8009041A external-priority patent/FR2480780B1/fr
Priority claimed from FR808026132A external-priority patent/FR2495636B2/fr
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of NL930133I1 publication Critical patent/NL930133I1/nl
Publication of NL930133I2 publication Critical patent/NL930133I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NL930133C 1980-04-22 1993-07-02 Vaccin tegen hepatitis B virus, werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin. NL930133I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8009041A FR2480780B1 (fr) 1980-04-22 1980-04-22 Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
FR808026132A FR2495636B2 (fr) 1980-12-09 1980-12-09 Procede de transformation de cellules, notamment eucaryotes, par un fragment d'adn circulaire du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn

Publications (2)

Publication Number Publication Date
NL930133I1 NL930133I1 (nl) 1993-11-01
NL930133I2 true NL930133I2 (nl) 1997-03-03

Family

ID=26221734

Family Applications (2)

Application Number Title Priority Date Filing Date
NL930132C NL930132I1 (nl) 1980-04-22 1993-07-02 Vaccin tegen hepatitis B virus werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin
NL930133C NL930133I2 (nl) 1980-04-22 1993-07-02 Vaccin tegen hepatitis B virus, werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL930132C NL930132I1 (nl) 1980-04-22 1993-07-02 Vaccin tegen hepatitis B virus werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin

Country Status (5)

Country Link
US (2) US5314808A (nl)
EP (1) EP0038765B1 (nl)
DE (1) DE3176404D1 (nl)
LU (2) LU88363I2 (nl)
NL (2) NL930132I1 (nl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297355B1 (en) 1978-12-22 2001-10-02 Biogen, Inc. Polypeptides displaying HBV antigenicity or hbv antigen specificity
US6455275B1 (en) 1980-02-25 2002-09-24 The Trustees Of Columbia University In The City Of New York DNA construct for producing proteinaceous materials in eucaryotic cells
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0062574A3 (en) * 1981-03-31 1982-12-29 The Regents Of The University Of California Virus protein synthesis
US4769238A (en) 1981-08-04 1988-09-06 The Regents Of The University Of California Synthesis of human virus antigens by yeast
ATE53235T1 (de) * 1981-08-04 1990-06-15 Univ California Synthese von menschlichen viralen antigenen mit hilfe von hefe.
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4741901A (en) * 1981-12-03 1988-05-03 Genentech, Inc. Preparation of polypeptides in vertebrate cell culture
JPS5936698A (ja) * 1982-08-20 1984-02-28 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えｄｎａおよび形質転換動物細胞
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
FR2560890B1 (fr) * 1984-03-07 1987-10-16 Grp Genie Genetique Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention
US5324513A (en) * 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
ES2167304T3 (es) * 1987-06-22 2002-05-16 Medeva Holdings Bv Peptido que contiene el antigeno de superficie de la hepatitis b.
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5733761A (en) * 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
CN1081069C (zh) * 1998-08-14 2002-03-20 饶纬华 乙型肝炎治疗性疫苗及其制备方法
CA2368655A1 (en) 1999-04-08 2000-10-19 Gregory M. Glenn Dry formulation for transcutaneous immunization
DE60236573D1 (de) 2002-04-05 2010-07-15 Pasteur Institut Identifizierung der Virulenz-assoziierten Regionen RD1 und RD5, die die Entwicklung von verbesserten Impfstoffen mit M. bovis BCG und M. microti ermöglicht
WO2007028167A2 (en) 2005-09-02 2007-03-08 Iomai Corporation Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof
CN102573883A (zh) 2009-06-12 2012-07-11 疫苗技术公司 用于促进细胞-介导的免疫应答的方法和组合物
US20130039947A1 (en) 2010-03-12 2013-02-14 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186193A (en) * 1975-06-16 1980-01-29 Merck & Co., Inc. Hepatitis B antigen
US4088748A (en) * 1976-11-02 1978-05-09 Merck & Co., Inc. Hepatitis B surface antigen
US4088746A (en) * 1976-11-11 1978-05-09 Bio-Rad Laboratories, Inc. Radioimmunoassay for thyroid-stimulating hormone (TSH)
US4181713A (en) * 1978-10-30 1980-01-01 Merck & Co., Inc. Isolation of HBs Ag
FR2444713A1 (fr) * 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
DD147855A5 (de) * 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
DE2942780A1 (de) * 1979-10-23 1981-05-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Eukaryotische zellen, eukaryotische protoplasten und vielzellige eukaryotische lebende organismen mit einem gehalt an durch lipidvesikel eingebrachter dna, verfahren zu ihrer herstellung von gen-produkten, zur immunisierung und zur behebung genetisch bedingter defekte
US4769238A (en) * 1981-08-04 1988-09-06 The Regents Of The University Of California Synthesis of human virus antigens by yeast
US4741901A (en) * 1981-12-03 1988-05-03 Genentech, Inc. Preparation of polypeptides in vertebrate cell culture
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
JPS5936698A (ja) * 1982-08-20 1984-02-28 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えｄｎａおよび形質転換動物細胞
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom

Also Published As

Publication number Publication date
DE3176404D1 (en) 1987-10-08
EP0038765A1 (fr) 1981-10-28
EP0038765B1 (fr) 1987-09-02
NL930133I1 (nl) 1993-11-01
US5314808A (en) 1994-05-24
US5591638A (en) 1997-01-07
LU88364I2 (fr) 1994-09-09
LU88363I2 (fr) 1994-09-09
NL930132I1 (nl) 1993-11-01

Similar Documents

Publication Publication Date Title
NL930133I2 (nl) Vaccin tegen hepatitis B virus, werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin.
IT7923395A0 (it) N-aril-ossazolidinoni, -ossazolidintioni, -pirrolidinoni, -pirrolidine e -tiazolidinoni, loro procedimento di preparazione eloro applicazione in terapia.
IT8224948A0 (it) Virus vaccinico modificato e metodi per la produzione ed uso del medesimo.
NL7904859A (nl) Anti-transpiratiemiddelen en werkwijze ter bereiding daarvan.
IT8125722A0 (it) Derivati amminoalchil-eterociclici, loro procedimento di preparazione eloro applicazione in terapia.
NL7904055A (nl) Tandmiddel, werkwijze voor de bereiding ervan en voor de bereiding van een zure waterhoudende silicagel.
ZA826154B (en) Infectious bronchitis vaccines for poultry, process for the preparation of such vaccines, process for preventing infectious broachitis and infectious bronchitis virus strain
NL7905375A (nl) Prostanoiden, werkwijze voor het bereiden daarvan, en daarop gebaseerde farmaceutische preparaten.
NL7804345A (nl) Imidazoazinen en imidazodiazinen, werkwijze ter berei- ding daarvan en farmaceutische preparaten.
NL7804230A (nl) N-alkyl-n-acylderivaten van thienamycine, werkwijze ter bereiding daarvan, alsmede farmaceutische preparaten.
NL7904059A (nl) Preparaat voor het reduceren van technetium, werkwijze voor de bereiding daarvan, en toepassingen daarvan.
NO822671L (no) Farmasoeytisk virksomme forbindelser og fremgangsmaate for deres fremstilling.
NL7802892A (nl) Pseudotrisacchariden, werkwijzen ter bereiding ervan en farmaceutische preparaten.
NL7900692A (nl) 2h-benzofuran-3-onderivaten en werkwijzen ter bereiding ervan.
ES519551A0 (es) Nuevas vacunas contra la bronquitis infecciosa.
BE878032A (nl) Hypo-beta-lipoproteinemisch dieticum werkwijze voor de bereiding en toepassing daarvan
PL197579A1 (pl) Sposob wytwarzania szczepionki wirusa rhinopneumonitis u konia
EG13435A (en) High molecular weight meningococal group c.vaccine and method for preparation thereof
DK48482A (da) Azopigmentpraeparater,fremgangsmaade til deres fremstilling og deres anvendelse
NL7903220A (nl) Mannich-base dispergeermiddelpreparaten en werkwijze ter bereiding daarvan.
NL174345C (nl) Zuur alkalicitraat, werkwijze ter bereiding daarvan en therapeutisch preparaat.
NL175524C (nl) Glycerolderivaten, deze bevattende farmaceutische preparaten, en werkwijze voor het bereiden daarvan.
NL7800753A (nl) Nieuw gesubstitueerd propylamine, werkwijze voor de bereiding, alsmede toepassing daarvan.
DK162771C (da) 17-oxazolinsteroider, samt fremgangsmaade til deres fremstilling
NL7803409A (nl) Werkwijze voor de bereiding van 4-hydroxy-5- -alkyl- en 4-hydroxy-2,5-dialkyl-3-oxo-2h- -furanen.